Skip to content
Boost Up Blog – Lifestyle
Author:
Jubilant Therapeutics
Jubilant Therapeutics Announces Oral Presentation of Preliminary Phase 1 Clinical Data for JBI-802, a First-in-Class Oral Dual LSD1/HDAC6 Inhibitor, in Essential Thrombocythemia and Related Myeloproliferative Neoplasms at the 68th ASH Annual Meeting
November 10, 2026
/DISREGARD RELEASE: Jubilant Therapeutics/
November 10, 2026
Jubilant Therapeutics Announces Oral Presentation of Phase 1 Clinical Results for JBI-802, a First-in-Class Oral Dual LSD1/HDAC6 Inhibitor, in Essential Thrombocythemia and Related Myeloproliferative Neoplasms at the 68th ASH Annual Meeting
November 10, 2026
Jubilant Therapeutics Announces First Preliminary Clinical Data from Ongoing Phase 1/2 Study of JBI-802 in Patients with Myeloproliferative Neoplasms at SOHO 2026
September 15, 2026